Pancreatic Cancer Research

ResearcherEhime UniversityActive in the last 2 years

Nobuaki Azemoto

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5007794457, A5024177981. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2013: 2 papers · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 10

  1. Outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in patients with early recurrent pancreatic cancer after adjuvant S-1 treatment: A propensity sco… Co-author DOI 10.1016/j.pan.2025.08.017↗
  2. Patients with Chronic Liver Disease under Surveillance for Hepatocellular Carcinoma Have a Favorable Long-Term Outcome for Pancreatic Cancer Due to Early Diagn… Co-author DOI 10.3390/cancers15030561↗
  3. Endoscopic duodenal stent placement versus gastrojejunostomy for unresectable pancreatic cancer patients with duodenal stenosis before introduction of initial … Co-author DOI 10.1093/jjco/hyab194↗
  4. Germline variants in cancer-predisposing genes in pancreatic cancer patients with a family history of cancer. Co-author DOI 10.1093/jjco/hyac110↗
  5. Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer. Co-author DOI 10.1097/md.0000000000027591↗
  6. ABO Blood Type and the Long-term Outcomes of Pancreatic Cancer. Co-author DOI 10.2169/internalmedicine.3748-19↗
  7. Early Detection of Pancreatic Cancer in Patients With Chronic Liver Disease Under Hepatocellular Carcinoma Surveillance. Co-author DOI 10.1016/j.mayocp.2018.12.034↗
  8. Efficacy of chemotherapy in elderly patients with unresectable pancreatic cancer: a multicenter review of 895 patients. Co-author DOI 10.1186/s12876-017-0623-8↗
  9. Improvement of long-term outcomes in pancreatic cancer and its associated factors within the gemcitabine era: a collaborative retrospective multicenter clinica… Co-author DOI 10.1186/1471-230x-13-134↗
  10. Increased B cell-activating factor promotes tumor invasion and metastasis in human pancreatic cancer. Co-author DOI 10.1371/journal.pone.0071367↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yoshinori Ohno · 7 shared papers, 2013–2023 · strength 0.61
  2. Mitsuhito Koizumi · 7 shared papers, 2013–2023 · strength 0.54
  3. Teru Kumagi · 7 shared papers, 2013–2023 · strength 0.54
  4. Yoichi Hiasa · 7 shared papers, 2013–2023 · strength 0.54
  5. Yoshinori Tanaka · 6 shared papers, 2013–2023 · strength 0.50
  6. Taira Kuroda · 6 shared papers, 2013–2023 · strength 0.50
  7. Takashi Terao · 5 shared papers, 2017–2023 · strength 0.47
  8. Kunihiro Tsuji · 3 shared papers, 2022–2025 · strength 0.42
  9. Masafumi Ikeda · 3 shared papers, 2022–2025 · strength 0.42
  10. Junji Furuse · 3 shared papers, 2022–2025 · strength 0.42
  11. Chigusa Morizane · 3 shared papers, 2022–2025 · strength 0.42
  12. Takeshi Terashima · 2 shared papers, 2022–2025 · strength 0.32
  13. Hiroaki Yanagimoto · 2 shared papers, 2022–2025 · strength 0.29
  14. Satoshi Kobayashi · 2 shared papers, 2022–2025 · strength 0.29
  15. Naohiro Okano · 2 shared papers, 2022–2025 · strength 0.29
  16. Yasuyuki Kawamoto · 2 shared papers, 2022–2025 · strength 0.29
  17. Makoto Ueno · 2 shared papers, 2022–2025 · strength 0.29
  18. Hiroshi Ishii · 3 shared papers, 2019–2022 · strength 0.27
  19. Nobumasa Mizuno · 2 shared papers, 2022 · strength 0.24
  20. Keiko Kamei · 1 shared paper, 2025 · strength 0.19
  21. Kumiko Umemoto · 1 shared paper, 2025 · strength 0.19
  22. Kei Nakagawa · 1 shared paper, 2025 · strength 0.19
  23. Masato Ozaka · 1 shared paper, 2025 · strength 0.19
  24. Hidetoshi Kitamura · 1 shared paper, 2025 · strength 0.19
  25. Akiko Todaka · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.